Lisata Therapeutics Begins Second Cohort Treatment In Bile Duct Cancer Trial

September 17, 2024 12:26 PM EDT | By Team Kalkine Media
 Lisata Therapeutics Begins Second Cohort Treatment In Bile Duct Cancer Trial
Image source: Shutterstock

Lisata Therapeutics Inc (NASDAQ:LSTA). has initiated treatment in the second-line cholangiocarcinoma (CCA) cohort of its BOLSTER trial. Cholangiocarcinoma, often referred to as bile duct cancer, is a rare and aggressive cancer with a five-year survival rate below 5%. This low survival rate underscores the significant need for advancements in treatment options.

The BOLSTER trial is a Phase 2a, multi-center trial that explores the efficacy of Lisata's investigational drug, certepetide, in combination with standard-of-care treatments for patients with first- or second-line CCA. This drug is designed to enhance the delivery and effectiveness of cancer therapies by improving penetration within tumors and altering the tumor microenvironment, potentially offering new hope for those affected by this condition.

Certepetide has demonstrated promising safety and efficacy profiles in earlier clinical trials. Additionally, it has been granted important designations such as Fast Track and Orphan Drug status for its potential role in treating various cancers. These designations aim to expedite the drug's development process and bring effective treatments to patients more quickly.

According to Lisata’s Chief Medical Officer, Dr. Kristen Buck, the decision to initiate treatment in the second-line cohort stems from recommendations made by investigators involved in the first-line cholangiocarcinoma cohort. Dr. Buck emphasized that the expansion of the trial seeks to improve outcomes for patients who have not responded to first-line treatments alone, reflecting the company's commitment to exploring new avenues for treatment.

Lisata Therapeutics has been gaining attention for its innovative approaches in cancer treatment, and certepetide is seen as a potential breakthrough for patients with hard-to-treat cancers like CCA. As the trial progresses, the company aims to gather more data to determine the drug’s broader impact and potential in improving patient survival rates.

This development marks another step forward for the healthcare sector in advancing cancer treatments, particularly for rare and challenging forms like cholangiocarcinoma


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.